

Ipsogen presents breast cancer biomarker results at the upcoming EBCC 5, the 5th European Breast Cancer Conference

Marseille, France, February 24, 2005 – Ipsogen SAS, the French cancer diagnostics company, announced today that its latest breast cancer program results had been selected for presentation at the EBCC 5 congress, the 5th European Breast Cancer Conference, held in Nice, France, 21-25 March 2006.

The abstract titled "Identification and validation of a genomic predictor to distinguish classes of patients with distinct outcomes among poor prognosis breast tumours after anthracycline-based adjuvant therapy", has been selected by the EBCC-5 Scientific Committee for oral presentation in the session "How should we do phase II/III trials in the age of molecular biology?". The session will be held on Wednesday 22 March 2006 and comprises talks from Invited Speakers along with the best submitted abstracts.

These results concern the identification on 323 patient samples and independent validation on 181 patient samples of a metagene-based predictor which is highly efficient to discriminate patients with unfavourable outcome after adjuvant anthracycline-based chemotherapy. It uses a validated combination of genes known for their biological relevance, and is valid irrespective of the clinical centre. The test was validated in an independent cohort with patient samples from a multicentric clinical trial. The study represents part of a research program that Ipsogen is conducting with FNCLCC (Paris, France), Institut Paoli-Calmettes (Marseille, France), Centre Léon Bérard (Lyon, France) and Institut Bergonié (Bordeaux, France).

Based on these findings and ongoing clinical studies, Ipsogen believes there is potential for applying this test to identify patients, at diagnosis, with favourable outcome under standard anthracyclines chemotherapy to avoid unnecessary chemotherapy intensification.

About Ipsogen

IPSOGEN is a biotechnology company utilising advanced technologies to analyse gene expression and to improve disease management of cancers. IPSOGEN addresses two main markets: (i) The molecular diagnosis of cancer (i.e.; leukaemia, lymphomas, breast cancer, colon cancer) to provide innovative diagnostic tools to clinical centres; (ii) the optimisation of cancer drug development, to provide pharmaceutical companies with high value information at the pre-clinical and clinical stages, and accelerate drug development through biomarker identification and validation. Headquartered in Marseille, France, IPSOGEN has global partnerships and markets its products worldwide.

This press release contains "forward-looking statements" as defined in the US Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Ipsogen SAS does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect the business of Ipsogen SAS, among others, the extent to which Ipsogen's technology platform can be used in large scale gene expression analysis, uncertainty of market acceptance of Ipsogen's technologies or ability to compete against existing technologies.

Contacts

Ipsogen: Dr Marc Essodaigui, Head of Business Development
Tel: +33 4 96190634 – essodaigui@ipsogen.com